These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 20839238)

  • 1. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect.
    Pioro EP; Brooks BR; Cummings J; Schiffer R; Thisted RA; Wynn D; Hepner A; Kaye R;
    Ann Neurol; 2010 Nov; 68(5):693-702. PubMed ID: 20839238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis.
    Panitch HS; Thisted RA; Smith RA; Wynn DR; Wymer JP; Achiron A; Vollmer TL; Mandler RN; Dietrich DW; Fletcher M; Pope LE; Berg JE; Miller A;
    Ann Neurol; 2006 May; 59(5):780-7. PubMed ID: 16634036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dextromethorphan/quinidine for the treatment of pseudobulbar affect.
    Patatanian E; Casselman J
    Consult Pharm; 2014 Apr; 29(4):264-9. PubMed ID: 24704895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dextromethorphan/quinidine: in pseudobulbar affect.
    Garnock-Jones KP
    CNS Drugs; 2011 May; 25(5):435-45. PubMed ID: 21476614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of dextromethorphan/quinidine on auditory event-related potentials in multiple sclerosis patients with pseudobulbar affect.
    Haiman G; Pratt H; Miller A
    J Clin Psychopharmacol; 2009 Oct; 29(5):444-52. PubMed ID: 19745644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial.
    Brooks BR; Thisted RA; Appel SH; Bradley WG; Olney RK; Berg JE; Pope LE; Smith RA;
    Neurology; 2004 Oct; 63(8):1364-70. PubMed ID: 15505150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of dextromethorphan/quinidine at two dosage levels for diabetic neuropathic pain: a double-blind, placebo-controlled, multicenter study.
    Shaibani AI; Pope LE; Thisted R; Hepner A
    Pain Med; 2012 Feb; 13(2):243-54. PubMed ID: 22314263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions.
    Pattee GL; Wymer JP; Lomen-Hoerth C; Appel SH; Formella AE; Pope LE
    Curr Med Res Opin; 2014 Nov; 30(11):2255-65. PubMed ID: 25062507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury.
    Hammond FM; Alexander DN; Cutler AJ; D'Amico S; Doody RS; Sauve W; Zorowitz RD; Davis CS; Shin P; Ledon F; Yonan C; Formella AE; Siffert J
    BMC Neurol; 2016 Jun; 16():89. PubMed ID: 27276999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Use of Combined Dextromethorphan and Quinidine in Patients With Dementia or Parkinson Disease After US Food and Drug Administration Approval for Pseudobulbar Affect.
    Fralick M; Sacks CA; Kesselheim AS
    JAMA Intern Med; 2019 Feb; 179(2):224-230. PubMed ID: 30615021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of pseudobulbar affect in ALS.
    Smith RA; Brooks BR
    Lancet Neurol; 2005 May; 4(5):270. PubMed ID: 15847840
    [No Abstract]   [Full Text] [Related]  

  • 12. Randomized open-label drug-drug interaction trial of dextromethorphan/quinidine and paroxetine in healthy volunteers.
    Schoedel KA; Pope LE; Sellers EM
    Clin Drug Investig; 2012 Mar; 32(3):157-69. PubMed ID: 22283559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of one-year dextromethorphan/quinidine treatment on management of respiratory impairment in amyotrophic lateral sclerosis.
    Sancho J; Ferrer S; Burés E; Luis Díaz J; Torrecilla T; Signes-Costa J; Servera E
    Respir Med; 2021 Sep; 186():106536. PubMed ID: 34260979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pseudobulbar affect in multiple sclerosis: toward the development of innovative therapeutic strategies.
    Miller A
    J Neurol Sci; 2006 Jun; 245(1-2):153-9. PubMed ID: 16674978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, Tolerability, and Effectiveness of Dextromethorphan/Quinidine for Pseudobulbar Affect Among Study Participants With Traumatic Brain Injury: Results From the PRISM-II Open Label Study.
    Hammond FM; Sauve W; Ledon F; Davis C; Formella AE
    PM R; 2018 Oct; 10(10):993-1003. PubMed ID: 29477412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose dextromethorphan in amyotrophic lateral sclerosis: phase I safety and pharmacokinetic studies.
    Hollander D; Pradas J; Kaplan R; McLeod HL; Evans WE; Munsat TL
    Ann Neurol; 1994 Dec; 36(6):920-4. PubMed ID: 7998781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dextromethorphan/quinidine: a review of its use in adults with pseudobulbar affect.
    Yang LP; Deeks ED
    Drugs; 2015 Jan; 75(1):83-90. PubMed ID: 25420446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic use of dextromethorphan: key learnings from treatment of pseudobulbar affect.
    Miller A; Panitch H
    J Neurol Sci; 2007 Aug; 259(1-2):67-73. PubMed ID: 17433820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dextromethorphan/quinidine (Nuedexta) for pseudobulbar affect.
    Med Lett Drugs Ther; 2011 Jun; 53(1366):46-7. PubMed ID: 21659969
    [No Abstract]   [Full Text] [Related]  

  • 20. Use of Compounded Dextromethorphan-Quinidine Suspension for Pseudobulbar Affect in Hospice Patients.
    Wahler RG; Reiman AT; Schrader JV
    J Palliat Med; 2017 Mar; 20(3):294-297. PubMed ID: 27997281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.